Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19
Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a national, multicenter, open-label, randomized, phase II/III trial that evaluates
the efficacy and safety of favipiravir and ribavirin in the treatment of patients with
confirmed COVID-19 observed within 72 hours. Approximately 100 patients will be randomized in
1:1 ratio and divided into two groups.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
The Scientific and Technological Research Council of Turkey
Collaborators:
Ankara City Hospital Bilkent Istanbul Umraniye Training and Research Hospital Koç University Monitor CRO